Roche (RHHBY) announced the FDA has approved Alecensa for adjuvant treatment following tumour resection for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer. The company said Alecensa is now the first and only ALK inhibitor approved for people with ALK-positive early-stage NSCLC who have undergone surgery to remove their tumour.
The approval was based on positive results from the Phase III ALINA study. The company noted that the data from the Phase III ALINA study will also be used for filing submissions to additional global health authorities, including the European Medicines Agency.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.